Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combined detection of GATA3 and E-cadherin is of great significance in the diagnosis and treatment of breast cancer, and it is expected to become an effective indicator for the diagnosis of breast cancer in the future.
|
31424658 |
2020 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer mutation in GATA3 zinc finger 1 induces conformational changes leading to the closer binding of ZnFn2 with a wrapping architecture.
|
31107186 |
2020 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
TTF-1 and napsin A for lung adenocarcinoma, p40 for squamous lung cancer, GATA3 and mammaglobin for breast cancer, or synaptophysin and chromogranin A for neuroendocrine tumors).
|
30354850 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Presence of CK7, GATA 3, and E cadherin tends to increase in mismatch repair deficient breast cancer.
|
30149959 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, LSD1 interacts with GATA3, a key luminal-specific transcription factor (TF), and their common target genes are highly related to breast cancer.
|
31409898 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pulmonary metastases of breast cancer were positive for GATA3 in 93% and CK7 in 78% of the cases, whereas 15% expressed CK5.
|
30389437 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Through this study, we identified possible GATA3-correlated genes and core pathways that play an important role, which requires further investigation in breast cancer.
|
30872657 |
2019 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The genomic landscape of MBC to some extent recapitulated that of smFBC, with recurrent PIK3CA (36%) and GATA3 (15%) somatic mutations, and with 40% of the most frequently amplified genes overlapping between both sexes.
|
31340200 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, the diagnostic utility of a panel of SOX10, GATA3, and androgen receptor (AR) in MBC negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 was evaluated and compared with the expression of these markers in the matched primary breast cancer.
|
30468800 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We discovered a role for GATA3 in suppressing epithelial-to-mesenchymal transition (EMT) in breast cancer by activating miR-455-3p expression.
|
31492753 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Heterozygous mutations in the transcription factor GATA3 are identified in 10-15% of all breast cancer cases.
|
31218575 |
2019 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine the prognostic and predictive roles of GATA3 genotypes for breast cancer.
|
30928413 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
GATA3 loss is associated with aggressive breast cancer development, but the mechanism by which breast cancer is affected by the loss of GATA3 function remains unclear.
|
31685800 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinicopathological characterization of CK7 negative breast cancer has not been addressed previously and similar studies on GATA3 negative tumors are limited.
|
31718619 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that GATA3 reduces the ATP level in the breast cancer microenvironment and inhibits breast cancer metastasis by up-regulating ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3).
|
31754326 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Application to 213 phenotypes and 1,544 TF binding datasets identified 2,264 relationships between hundreds of TFs and 94 phenotypes, including androgen receptor in prostate cancer and GATA3 in breast cancer.
|
29662164 |
2018 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
GATA3 is a master regulator that drives mammary epithelial cell differentiation, and the suppression of GATA3 expression is associated with the development of aggressive breast cancer.
|
29510139 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, we demonstrated that FBXW7α inhibits breast cancer cells survival through destabilizing GATA3, and the expression level of FBXW7α is negatively correlated with that of GATA3 in breast cancer samples.
|
28722108 |
2018 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The histopathologic features and the expression of GATA3, cytokeratin (CK)7, mammaglobin staining and estrogen and progesterone receptors led to a diagnosis of breast cancer originating from the ectopic mammary tissue in the vulva.
|
30125424 |
2018 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Heterozygous GATA3 mutations occur in up to 15% of estrogen receptor (ER)-positive breast tumors and have been proposed to be null alleles resulting in haploinsufficiency; however, the mutation spectrum of GATA3 in breast cancer is in sharp contrast to that found in HDR syndrome, a true GATA3 haploinsufficiency disease.
|
30061207 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Even though GATA3 expression has been reported in many benign and malignant adnexal tumors (mostly of sebaceous, follicular, and apocrine differentiation), as well as in many other neoplasms, GATA3 staining to differentiate PCACC from skin breast cancer metastasis has a high negative predictive value.
|
29431200 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Kaplan-Meier survival analyses showed that ER+/progesterone receptor (PgR)+ and lower grade BC patients with relatively high GATA3 had better clinical overall survival (OS).
|
29902578 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Despite numerous studies on the utility of GATA-3 as breast cancer marker, its comparison with other breast markers, its concordance between primary and metastatic tumors and its expression in primary cancers from sites with frequent breast metastases remains unclear.
|
29340880 |
2018 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor expression is strongly correlated with GATA3 in breast cancer, particularly in tumors with lobular morphology.
|
29408697 |
2018 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although GATA3 levels remained unaltered between primary breast cancer and pleural metastases, FOXA1 levels were reduced exclusively in metastases of patients who received endocrine therapies in the adjuvant setting, even though ERα was still expressed.
|
29972720 |
2018 |